Department of Pathology, Sri Ramachandra University, Porur, Chennai - 600 116, India

Background: There may be two fundamentally distinct pathogenic types of disease, type I (oestrogen linked, endometrioid type) and type II, based on differences in the biological behaviour of endometrial cancer in epidemiology, presentation, and prognosis (non-estrogen related, non-endometrioid type). It's critical to distinguish between the two types of hyperplasia since the latter can progress to an endometrioid kind of cancer if left untreated. There have been few research on the biology of hyperplastic lesions reported from India, in contrast to cervical malignancies. This 16-year retrospective study examined the nature and prognosis of proliferative endometrial lesions in a south Indian referral centre.

On endometrial biopsy and hysterectomy specimens during a 16 year period (1983 to 1999), a histological diagnosis of the endometrial hyperplasia, polyp, and cancer was made. The case slides were then evaluated. The patients who had received a subsequent or prior biopsy more than once were located using the computer programme Foxpro. In the follow-up cases, an effort was made to check for lesion advancement, regression, or static characteristics.

Of the 1778 instances examined, only 74 patients received follow-up endometrial histology, including five occurrences of benign endometrial polyp. There were 59 cases of simple hyperplasia, 10 cases of complex hyperplasia without atypia, and 5 cases of atypia in the hyperplasia patients. Patients with all sorts of hyperplasias were mostly between the ages of 41 and 50. Lesions changed to a normal pattern in 10.81% of cases, advanced to a higher grade in 8.10%, declined to a lower grade in 9.45%, and persisted in 70.27% of cases. In 54 patients, a mixed pattern was observed; the most common coexisting lesion was simple and complex hyperplasia without atypia.

The outcome of the endometrium's hyperplastic lesion revealed a variety of patterns. Most follow-up instances revealed the lesion's permanence, which may be brought on by a fluctuating but greater degree of estrogenic stimulation. As a result, it wasn't just the presence of large quantities of oestrogen but also its long-term maintenance that affected biology.

Keywords: result, preneoplastic, endometrium

It was Recamier in 1850, who originally perceived the state of endometrial hyperplasia.[1] Endometrial hyperplasia is the consequence of a tireless, delayed, estrogenic feeling of the endometrium. The most well-known cause being rehashed anovulatory cycles. Hyperplasia may likewise result from inordinate endogenous creation or exogenous organization of estrogens.[2] For a long time, pathologists have been worried about the dangerous capability of different sorts of endometrial hyperplasias.Very nearly quite a while back, Hertig and Sommers, proposed the hypothesis of movement of endometrial hyperplasia to adenocarcinoma, going through a phase of abnormal changes.[1] Adenomatous and abnormal hyperplasias are accounted for to be the normal forerunners of endometrial carcinoma.[3] Fox and Buckley caused us to notice the way that these hyperplastic sores address a solitary illness spectrum.[4] Nonetheless, a large portion of the examinations reported in writing are an impression of western measurements. The current review study was intended to decide the nature and result of proliferative sores of the endometrium during a 16-year time span in a reference medical clinic in South India.

Endometrial biopsies or hysterectomy examples with determination of endometrial hyperplasia, endometrial polyp, and adenocarcinoma, from 1983 to 1999, were remembered for the review. The subtleties of patients remembered for this study were gotten from the histopathology demand documents and kept in an organized proforma, which was then taken care of into the PC. Utilizing the Foxpro programming, patients with more than one endometrial biopsy or who had ensuing hysterectomy were recognized. The histopathological status of the endometrium was explored and related with the clinical history and an endeavor was made to search for movement, relapse or a static nature of the sore.The endometrial hyperplasias were grouped by the World Wellbeing Association (WHO) order, as straightforward hyperplasia without atypia (SH), basic hyperplasia with atypia (SHA), complex hyperplasia without atypia (CH), and complex hyperplasia with atypia (CHA).

In affluent nations, endometrial carcinoma is the most prevalent malignant tumour of the female genital tract. Endometrial cancer has two distinct biological subtypes, type I (estrogen-related, endometrioid type), and type II, which are distinguished by differences in epidemiology, presentation, and biological activity (non-estrogen related, non-endometrioid type). [5] Endometrial hyperplasia is a common scenario for the development of type 1 endometrial cancer, which has an endometrioid histology and a propensity to be physiologically inert. [5] The menstrual periods of patients with hyperplasia are anovulatory, and some of them may be using exogenous oestrogen. Although anovulatory cycles can occur at menarche and in postmenopausal women, hyperplasia is less common in younger women, likely because endometrial biopsies are rarely used to diagnose bleeding in menarcheal women. The youngest participant in the current study was a 12-year-old with SH. She was younger than the person described in the written word. [6] For all types of hyperplasia and endometrial polyps, the age range from 41 to 50 years old was the most prevalent. This is the age bracket when SH is most prevalent, according to Schroder et al. [7] Due to their frequent anovulatory cycles, elderly women experience endometrial hyperplasia more frequently during the climacteric stage.

Clearly variable oestrogen production indicates that this is the age range when ovarian function is transitioning. Hyperplasia is not very frequent during the reproductive years. Given that androstenedione is peripherally converted to oestrogen in adipose tissue, obese women with polycystic ovarian disease may also experience hyperplasia. Unopposed oestrogen replacement therapy causes postmenopausal women to develop hyperplasia. [8] It has been hotly argued whether hyperplasia and cancer are related. Numerous studies have shown that endometrial hyperplasia and cancer have a tight association. Gusberg et al. noted in 1961 that women with AH had a cumulative risk of endometrial cancer that was considerably higher than that of women without hyperplasia over the course of 9 to 10 years. [9] In a long-term investigation, Chamlian and Taylor discovered that 14% of adenomatous and atypical hyperplasias later transformed into cancer. [10] Another point of view contends that endometrial hyperplasia and adenocarcinoma may be two distinct manifestations of endometrial pathology that can coexist but need not necessarily do so. [11] Less than 0.4% of cases of cystic hyperplasia that were investigated by McBride for up to 24 years progressed to cancer. [12] The destiny of a hyperplastic sore of the endometrium in the current review showed a differed design.

likewise found a high level of relapse incorporating cases with elements of atypia. Notwithstanding, they found just a single case that advanced to adenocarcinoma.[13] Studies done by Yokosuka et al. furthermore, Kurman et al, likewise showed a higher level of relapse when contrasted with our own, this might be because of the explanation that the majority of the patients in their follow up were being treated with progesterone.[14,15] Our review showed relapse to a milder sore in 9.55% of the cases and inversion to ordinary example in 10.81% of the cases. A lower level of case relapse in our review could be connected with an efficient foundation, ignorance, and absence of consistence to treatment, as this is a reference government medical clinic with patient portrayal overwhelmingly from provincial regions. In the greater part of our cases the essential sores persevered on follow up. The determination of the injury could maybe be made sense of by elevated degree of estrogenic improvement with potential time periods. The sore, which had advanced to a higher grade, would have come about because of supported elevated degrees of estrogen. In our review, the sore continued even following five years if there should be an occurrence of SH and for a very long time in the event of a harmless endometrial polyp, a finding that could be because of fluctuating estrogen levels, not permitting the sore to advance or relapse.

Then again a supported more elevated level might have brought about movement to a higher grade According to Kurman et al. (1985), atypical hyperplasia takes an average of 4.1 years to transform into cancer. [15] If a hysterectomy was carried out within one month of curettage, between 17 to 25% of women with atypical hyperplasia who had been detected during curetting might have developed a well-differentiated cancer in the uterus. [15] In our investigation, one instance of complicated hyperplasia with atypia quickly developed into cancer over the course of one month. Therefore, it is important to note that endometrial cancer is quite prevalent in people who have an atypical hyperplasia. Therefore, doctors and patients should consider the high likelihood of concomitant carcinoma when selecting therapy methods for women with atypical hyperplasia. [16] The quantities of planned investigations have been little and the genuine normal history of the problem couldn't be seen because of the organization of different types of treatments. Review studies may then again give a one-sided and unduly melancholy perspective on the gamble of adenocarcinoma.

Endometrial hyperplasia of anything type should be considered as an advance notice sign that an endometrium is noncycling and in this way vulnerable to neoplastic occasions. The simple presence of hyperplasia isn't a reason for hysterectomy. Be that as it may, as a rule, the more extreme the hyperplasia the more probable it is to be trailed by intrusive carcinoma. Opportune treatment can assist with giving a climate to the injury to relapse and keep away from extremist medical procedures. A few examiners have tracked down useful impacts from treating hyperplasia and carcinoma with progesterone.

Kistner, treated patients with abnormal hyperplasia and patients with carcinoma in situ with progesterone and observed that the sores were reversible and none advanced.[17] All endometrial hyperplasias seem to be caused by excessive oestrogen stimulation, however the link is less obvious for cystic hyperplasia than it is for atypical hyperplasia. [18] This would lead one to predict that two foci of hyperplasia would frequently be found in the same uterus. Therefore, finding an endometrium with pockets of atypical hyperplasia in addition to extensive cystic hyperplasia is not uncommon. [4,18] Whether the latter evolves from the former is up for debate. One may argue that endometrial glands that have been repeatedly stimulated by estrogens over time may change how they react and eventually multiply in an atypical rather than cystic manner. [4,18] The two types of hyperplasia could, however, occur simultaneously, with varied effect being the result of the variance in response from one part of the endometrium to another. [18] There were 54 cases in this study that demonstrated the co-existence of different subtypes of endometrial hyperplasia and cancer.

This could be as a result of the fact that they either form a continuous spectrum or they express a common underlying growth defect. [4] Complex and atypical hyperplasias predominated among the combined lesions seen in our investigation, indicating a close connection between them. Except for adenomatous hyperplasia (now classified as CH), which is typically observed alone, other forms of hyperplasia, according to Fox and Buckley, can coexist with one another. [4] Contrarily, we discovered CH coexisting with Atypical hyperplasias and SH.

The most frequent reason for irregular uterine bleeding is endometrial polyps. Rarely is a complex or atypical kind of hyperplasia found inside a polyp in a biopsy or polypectomy material. It is currently unknown if the hyperplasia will most likely only affect the polyp or also affect an endometrium that isn't polypoid. [19] We had a very small number of patients in our study to evaluate this possibility, but we did discover progression to SH in one case and a mixed pattern with SH and CH in 12 cases. This can make us consider the possibility that they are all connected. A low frequency of premalignant and malignant lesions in endometrial polyps was discovered in a study by Antunes et al. [20] Their research also revealed that cancer was more common in older women and those who had postmenopausal haemorrhage, necessitating hysteroscopic removal of the endometrial polyps in these situations. [20] In their investigation, Kelly et al. found that there was a considerable chance of endometrial hyperplasia in a polyp while also including a non-polypoid endometrium. [19] The patient will need numerous consultations due to the nature of the condition. Although this was a 16-year retrospective analysis, only a small number of patients visited our facility for further follow-up. As a result, there was a risk that patients' tracability had been compromised, either because they had misplaced their out-patient identification card and reregistered at our facility using a new identity number or because they had transferred to another facility for subsequent visits.

The patient will need numerous consultations due to the nature of the condition. Although this was a 16-year retrospective analysis, only a small number of patients visited our facility for further follow-up. As a result, there was a risk that patients' tracability had been compromised, either because they had misplaced their out-patient identification card and reregistered at our facility using a new identity number or because they had transferred to another facility for subsequent visits for academic objectives. Early diagnosis, consistent monitoring, and appropriate care can stop the progression of a disease.

1. O’Dowd MJ, Philipp EE. The history of Obstetrics and Gynaecology. 1st ed. New York: Parthenon Publishing Group; 1994. Cancer of the uterus; pp. 571–80. [Google Scholar]

2. Ronnett BM, Kurman RJ. Precursor lesions of endometrial carcinoma. In: Kurman RJ, editor. Blaustein’s Pathology of the Female Genital Tract. 5th ed. New York: Springer-Verlag; 2002. pp. 467–500. [Google Scholar]

3. Gusberg Sb, Moore Db, Martin F. Precursors of corpus cancer: A clinical and pathological study of adenomatous hyperplasia. Am J Obstet Gynecol. 1954;68:1472–81. [PubMed] [Google Scholar]

4. Fox H, Buckley CH. The endometrial hyperplasias and their relationship to endometrial neoplasia. Histopathology. 1982;6:493–510. [PubMed] [Google Scholar]

5. Horn LC, Meinel A, Handzel R, Einenkel J. Histopathology of endometrial hyperplasia and endometrial carcinoma: An update. Ann Diagn Pathol. 2007;11:297–311. [PubMed] [Google Scholar]

6. Lee KR, Scully RE. Complex endometrial hyperplasia and carcinoma in adolescents and young women 15 to 20 years of age: A report of 10 cases. Int J Gynecol Pathol. 1989;8:201–13. [PubMed] [Google Scholar]

7. Schroder R. Endometrial hyperplasia in relation to genital function. Am J Obstet Gynecol. 1954;68:294–309. [PubMed] [Google Scholar]

8. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA, King RJ. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med. 1981;305:1599–605. [PubMed] [Google Scholar]

9. Gusberg SB, Hall RE. Precursors of endometrial carcinoma. Obstet Gynecol. 1961;17:397–412. [PubMed] [Google Scholar]

10. Chamlian DL, Taylor HB. Endometrial hyperplasia in young women. Obstet Gynecol. 1970;36:659–66. [PubMed] [Google Scholar]

11. Koss LG. Diagnostic Cytology and its histopathologic bases. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 1992. Proliferative disorders and carcinoma of the endometrium; pp. 422–465. [Google Scholar]

12. McBride JM. Premenopausal cystic hyperplasia and endometrial carcinoma. J Obstet Gynaecol Br Emp. 1959;66:288–96. [PubMed] [Google Scholar]

13. Tabata T, Yamawaki T, Yabana T, Ida M, Nishimura K, Nose Y. Natural history of endometrial hyperplasia: Study of 77 patients. Arch Gynecol Obstet. 2001;265:85–8. [PubMed] [Google Scholar]

14. Yokosuka K, Teshima H, Yamakawa Y, Hasumi K. Characteristic of cystic glandular hyperplasia as a precursor of endometrial carcinoma. Nippon Sanka Fujinka Gakkai Zasshi. 1994;46:1241–6. [PubMed] [Google Scholar]

15. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985;56:403–12. [PubMed] [Google Scholar]

16. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ, 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: A Gynecologic Oncology Group study. Cancer. 2006;106:812–9. [PubMed] [Google Scholar]

17. Kistner RW. Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium. Cancer. 1959;12:1106–22. [PubMed] [Google Scholar]

18. Anderson MC. Endometrial hyperplasia. In: Anderson MC, Symmers WC, Fox H, editors. Female reproductive system, Systemic pathology. 3rd ed. Edinburgh: Churchill Livingstone; 1991. pp. 171–84. [Google Scholar]

19. Kelly P, Dobbs SP, McCluggage WG. Endometrial hyperplasia involving endometrial polyps: Report of a series and discussion of the significance in an endometrial biopsy specimen. BJOG. 2007;114:944–50. [PubMed] [Google Scholar]

20. Antunes A, Jr, Costa-Paiva L, Arthuso M, Costa JV, Pinto-Neto AM. Endometrial polyps in pre-and postmenopausal women: factors associated with malignancy. Maturitas. 2007;57:415–21. [PubMed] [Google Scholar]

Sandhya Sundaram . Preneoplastic endometrial conditions' biological behaviour: a 16-year retrospective study in southern India. World Journal Of Hematology And Oncology 2022.